Hemoglobin synthesis is a coordinated effort between two separate production lines running inside the same cell: one builds heme, the iron-containing pigment that binds oxygen, and the other builds globin, the protein that wraps around it. These two components are manufactured through distinct biochemical pathways and then snapped together in developing red blood cells in the bone marrow. The process is tightly regulated at every level, from gene activation to protein folding to iron delivery, because even a small mismatch between heme and globin output can damage or destroy the cell.
Two Production Lines, One Cell
A mature hemoglobin molecule is a four-part structure: two alpha-globin chains and two beta-globin chains, each cradling its own heme group. That means the cell needs to produce four globin proteins and four heme molecules, then assemble them into a single functional unit. The alpha and beta chains are encoded by genes on entirely different chromosomes, and heme is built through an eight-step enzymatic pathway that bounces between the mitochondria and the cytoplasm. Despite this complexity, the finished hemoglobin accumulates so efficiently during red blood cell development that it makes up roughly a third of the cell’s total weight by the time the cell is ready to enter the bloodstream.
The process plays out inside erythroid precursor cells in the bone marrow. As these cells mature toward becoming red blood cells, they progressively shrink, condense their DNA, and eventually eject their nucleus entirely. Throughout this maturation, hemoglobin production ramps up steadily, so that the final, nucleus-free red blood cell is essentially a bag of hemoglobin optimized for gas transport.1PubMed Central. Recent updates of stem cell-based erythropoiesis
Building Heme From Scratch
Heme synthesis begins in the mitochondria with an enzyme called ALAS (5-aminolevulinate synthase), which combines two simple molecules, glycine and succinyl-CoA, to produce a compound called ALA (5-aminolevulinate). This is the rate-limiting first step, meaning it sets the pace for the entire pathway.2PubMed Central. 5-Aminolevulinate synthase catalysis: The catcher in heme biosynthesis In red blood cell precursors, a dedicated version of this enzyme, ALAS2, handles the job. There is a separate version, ALAS1, that operates in other tissues, but erythroid cells rely on ALAS2 because its production is tuned to the cell’s iron supply in a way ALAS1 is not.
Once ALA is made, it leaves the mitochondria and enters the cytoplasm, where the next several enzymes in the pathway take over. ALA dehydratase combines two ALA molecules into a larger ring-shaped compound, and subsequent enzymes modify and rearrange the structure through several intermediate stages, gradually building the porphyrin ring that gives heme its shape. The pathway then circles back to the mitochondria for the final step, where an enzyme called ferrochelatase inserts a single iron atom into the center of the porphyrin ring. That insertion produces heme.3PubMed Central. Ferrochelatase: Mapping the Intersection of Iron and Porphyrin Metabolism in the Mitochondria
The geography matters. The pathway’s start and finish both happen inside mitochondria, with the middle steps occurring in the cytoplasm. Intermediates have to be actively shuttled across mitochondrial membranes at multiple points. If any of the eight enzymes in the chain is defective or inhibited, porphyrin intermediates can pile up in the wrong compartment and cause disease, a group of conditions collectively called porphyrias.
Getting Iron to the Right Place
Heme cannot be completed without iron, and getting iron into erythroid cells is a process in itself. Most iron in the blood is bound to a carrier protein called transferrin. Developing red blood cells are covered in transferrin receptors that grab iron-loaded transferrin from the bloodstream and pull it inside the cell.4PubMed Central. Mammalian iron transport Once inside, the iron is released and routed to the mitochondria, where ferrochelatase is waiting to plug it into protoporphyrin.
Much of the iron used in new hemoglobin is not freshly absorbed from food. Instead, it comes from old red blood cells. After about 120 days in circulation, aging red blood cells are engulfed by specialized immune cells called macrophages, mainly in the spleen and liver. These macrophages break down the hemoglobin, strip out the iron, and release it back into the blood on transferrin so it can be recycled into new hemoglobin.5Journal of Innate Immunity. Macrophages and Systemic Iron Homeostasis This recycling loop is remarkably efficient. You absorb only a small amount of dietary iron each day to replace what is lost through skin shedding, intestinal cell turnover, and minor bleeding; the vast majority of the iron in your hemoglobin has already been around the loop many times.
Turning On Globin Genes
While heme is being assembled enzymatically, the globin side of the equation depends on gene transcription. Humans have separate clusters of globin genes: the alpha-globin genes sit on chromosome 16, and the beta-globin genes sit on chromosome 11. Making hemoglobin requires both clusters to be actively read at the same time, in the same cell, at similar rates.
The beta-globin gene cluster has a particularly well-studied control switch called the locus control region (LCR), a stretch of DNA upstream of the globin genes that acts as a master activator. Without the LCR, the beta-globin genes essentially stay silent even when all their local promoters and enhancers are intact.6PubMed Central. Locus control regions The LCR works as an integrated unit: its multiple hypersensitive sites cooperate to open up the surrounding chromatin and physically contact individual globin gene promoters to turn them on. Deleting even a single key element within the LCR severely depresses globin gene expression at every developmental stage.7PubMed. Hypersensitive site 2 specifies a unique function within the human beta-globin locus control region to stimulate globin gene transcription
There is also a feedback loop connecting heme availability to globin gene activation. A transcription factor called Bach1 normally sits on parts of the LCR and represses beta-globin expression. When heme levels rise inside the cell, heme binds directly to Bach1, kicking it off the DNA and allowing globin transcription to proceed. This means that as heme production increases, the cell automatically ramps up globin production to match.8PubMed. Heme positively regulates the expression of beta-globin at the locus control region via the transcriptional factor Bach1 in erythroid cells
Balancing Heme and Globin Through Translation
Beyond the transcription-level link, the cell has a second layer of coordination that operates at the point where messenger RNA is translated into protein. A sensor kinase called HRI (heme-regulated inhibitor) monitors heme levels inside erythroid cells. When heme is abundant, HRI stays inactive and globin production proceeds at full speed. When heme runs low, HRI switches on and phosphorylates a key translation factor, eIF2α, which slams the brakes on globin mRNA translation.9PubMed Central. The heme-regulated inhibitor kinase requires dimerization for heme-sensing activity
This is a safety mechanism. Globin chains without heme are unstable and toxic; they can misfold, aggregate, and damage the cell from within. By tying globin translation directly to heme availability, HRI ensures the cell does not flood itself with heme-free globin during a shortage. At the same time, HRI activation during heme deficiency triggers a stress-response program that helps the cell cope, in part by boosting the production of stress-response genes through a transcription factor called ATF4.10PubMed Central. Heme-regulated eIF2α kinase in erythropoiesis and hemoglobinopathies HRI also suppresses heme biosynthetic enzymes when heme is scarce, preventing the cell from burning through raw materials it cannot use productively.11PubMed Central. Translational control by heme-regulated eIF2α kinase during erythropoiesis
Folding and Assembly
Once alpha and beta chains have been synthesized and heme groups have been produced, the pieces need to come together. Each globin chain folds into a characteristic three-dimensional shape and binds one heme molecule. Two alpha-heme units and two beta-heme units then pair up to form the finished hemoglobin tetramer. This assembly is not passive; it depends on molecular chaperones that prevent newly made chains from aggregating before they find their partner.
Alpha chains are particularly vulnerable to aggregation because they are often produced slightly faster than beta chains. A dedicated chaperone protein called AHSP (alpha-hemoglobin-stabilizing protein) addresses this problem. AHSP binds free alpha chains and holds them in a stable, soluble state until a beta chain becomes available for pairing.12PubMed Central. Alpha-hemoglobin-stabilizing protein: an erythroid molecular chaperone Without AHSP, excess alpha chains would precipitate and damage the developing red blood cell. This chaperone role becomes especially critical in conditions like beta-thalassemia, where beta-chain production is reduced and large surpluses of alpha chains accumulate.13PubMed. Alpha-hemoglobin-stabilizing protein (AHSP): a modulatory factor in β-thalassemia
The finished tetramer, with its two alpha-beta dimers locked together, is what gives hemoglobin its ability to cooperatively bind oxygen: picking up the first oxygen molecule makes it easier to pick up the next, and releasing the first makes it easier to release the rest. That cooperative behavior depends on the structural interplay between all four subunits and the iron-histidine bond that anchors each heme to its globin chain.14PubMed Central. Structural origin of cooperativity in human hemoglobin: a view from different roles of α and β subunits in the α(2)β(2) tetramer
The Fetal-to-Adult Hemoglobin Switch
The beta-globin gene cluster does not just contain one gene. It holds several globin genes that are activated at different stages of life: embryonic epsilon-globin, fetal gamma-globin, and adult beta-globin (plus the minor adult delta-globin). During fetal development, red blood cells predominantly produce gamma-globin, which pairs with alpha-globin to form fetal hemoglobin (HbF). HbF binds oxygen more tightly than adult hemoglobin, which helps the fetus pull oxygen from the mother’s blood across the placenta. Around birth, the switch begins: gamma-globin genes are gradually silenced and beta-globin genes are turned on, so that by a few months of age, adult hemoglobin (HbA) predominates.
This switch is orchestrated by several key regulatory proteins. BCL11A emerged from genetic studies as a potent silencer of fetal hemoglobin; it actively represses gamma-globin expression in adult erythroid cells. Another factor, KLF1, both activates beta-globin transcription and drives expression of BCL11A itself, acting as a kind of master coordinator.15PubMed Central. Update on fetal hemoglobin gene regulation in hemoglobinopathies MYB is a third player that influences the timing of the switch.16PubMed Central. The switch from fetal to adult hemoglobin
Understanding this switch has direct medical relevance. In sickle cell disease and beta-thalassemia, the adult beta-globin gene is defective. If you could reactivate fetal hemoglobin in adult red blood cells, you could compensate for the broken adult version. That is exactly the strategy behind some current gene therapies, which target BCL11A to re-awaken gamma-globin production and boost HbF levels in patients’ blood.
The Bigger Regulatory Picture: Oxygen, EPO, and the Kidney
Hemoglobin synthesis does not run at a fixed rate. The body adjusts it based on oxygen demand. When tissues become oxygen-starved, whether from anemia, high altitude, or lung disease, a class of oxygen-sensing proteins called hypoxia-inducible factors (HIFs) activate in the kidneys and liver. HIF-2 in particular drives the production of erythropoietin (EPO), a hormone that travels through the blood to the bone marrow and tells erythroid precursor cells to multiply and mature faster.17PubMed Central. Regulation of erythropoiesis by hypoxia-inducible factors More precursor cells means more cells synthesizing hemoglobin, which means more oxygen-carrying capacity.
HIF-2 also boosts intestinal iron absorption, ensuring that the raw material supply keeps pace with increased demand. This dual role, stimulating both EPO production and iron uptake, makes HIF-2 a central node in the body’s response to oxygen deficiency. It is also why EPO has been abused as a performance-enhancing drug in endurance sports: exogenous EPO forces the body into overdrive, producing extra red blood cells packed with hemoglobin even when oxygen levels are perfectly normal.
When Synthesis Goes Wrong
Disruptions at nearly any step of hemoglobin synthesis can cause disease. The most common problems fall into a few categories.
Thalassemias
The thalassemias result from imbalanced globin chain production. In beta-thalassemia, mutations in or near the beta-globin gene reduce or eliminate beta-chain output. The alpha chains that continue to be made at normal rates have no partner to bind, so they precipitate inside erythroid precursor cells, damaging their membranes and triggering their premature destruction, a process called ineffective erythropoiesis.18PubMed Central. Imbalanced globin chain synthesis determines erythroid cell pathology in thalassemic mice The result is severe anemia despite the bone marrow working overtime to produce red cells.19PubMed Central. Pathophysiology and Clinical Manifestations of the β-Thalassemias Alpha-thalassemia works the same way in reverse: reduced alpha-chain output leaves excess beta chains, which form unstable tetramers on their own.
Porphyrias and Sideroblastic Anemias
Defects in the heme pathway cause a different set of diseases. When ALAS2 loses function, erythroid cells cannot make enough ALA to feed the heme pipeline. Iron keeps arriving via transferrin, but there is not enough porphyrin ring to incorporate it. The iron piles up inside mitochondria, forming characteristic ring sideroblasts visible under a microscope, leading to X-linked sideroblastic anemia.20PubMed. Regulation and tissue-specific expression of δ-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias In the opposite scenario, certain gain-of-function mutations in ALAS2 crank up protoporphyrin production beyond what the cell needs for heme, causing X-linked protoporphyria. Excess protoporphyrin leaks into the skin and triggers painful photosensitivity when exposed to light.21PubMed Central. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload
Lead Poisoning
Lead provides a textbook case of environmental interference with heme synthesis. Lead strongly inhibits ALA dehydratase, the second enzyme in the heme pathway, by binding to the enzyme’s sulfur-containing active sites. Studies of lead-exposed workers show a clear dose-dependent drop in ALA dehydratase activity as blood lead levels rise, along with accumulation of zinc-protoporphyrin, a marker that heme is being assembled with zinc instead of iron because the pathway is clogged upstream.22PubMed Central. Impact of chronic lead exposure on selected biological markers Lead also hits ferrochelatase, the final enzyme. The combined effect is a hemoglobin deficit that manifests as anemia, and it is one reason lead exposure is so dangerous in children, whose rapidly growing bodies rely heavily on efficient red blood cell production.23PubMed. Pyruvate kinase activity and δ-aminolevulinic acid dehydratase activity as biomarkers of toxicity in workers exposed to lead
How Hemoglobin Evolved Its Complexity
The four-subunit structure of hemoglobin, with its elegantly cooperative oxygen binding, did not appear all at once. Ancestral protein reconstruction work published in Nature traced the evolutionary history backward and showed that the earliest ancestor of vertebrate hemoglobin was a simple monomer, a single globin protein that bound oxygen on its own. Over time, gene duplication produced a homodimer, a two-copy version that had high oxygen affinity but lacked cooperativity, essentially the evolutionary “missing link.” Only after a further gene duplication created distinct alpha and beta subunit types did the modern cooperative tetramer emerge.24Nature. Origin of complexity in haemoglobin evolution
That cooperative binding, the ability to shift between a high-affinity and low-affinity state, is what makes hemoglobin so effective as an oxygen shuttle. It loads up in the lungs where oxygen is plentiful and dumps its cargo in tissues where oxygen is scarce. A simpler protein with fixed affinity could not do both jobs well. The evolution from monomer to cooperative tetramer was not a single leap but a stepwise accumulation of structural changes, each of which had to be compatible with the cell’s existing synthesis and assembly machinery. The synthesis pathway we see today, with its elaborate coordination of heme and globin, co-evolved with the protein it produces.
Why Red Blood Cells Make Hemoglobin and Nothing Else
One unusual feature of erythroid development is how single-minded it becomes. As a red blood cell precursor matures, it shuts down most of its other protein-production programs and devotes an increasing share of its resources to hemoglobin. By the reticulocyte stage, when the cell has expelled its nucleus but still retains some ribosomes, virtually all new protein being made is globin. This extreme specialization is the reason the HRI checkpoint matters so much: there is no plan B for a cell that has staked everything on hemoglobin and runs into a heme supply problem.
The enucleation step itself, when the maturing cell pushes out its nucleus, is the point of no return. Without a nucleus, the cell can no longer transcribe new genes. It lives out its roughly 120-day lifespan running on the hemoglobin and enzymes already inside it, until macrophages in the spleen recognize it as old, consume it, and ship the iron back to the bone marrow for the next generation of red blood cells to use.